Found 8 Fallopian Tube Cancer trials
A listing of Fallopian Tube Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
The purpose of this study includes the following: · To test the efficacy and safety of the Study Drug and to find out what effects, good and/or bad, it has on you and your cancer. · To understand how the body absorbs and processes the Study Drug by measuring the …
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 3
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made by the body which in turn may …
A Phase 2 Open-label Study Evaluating the Efficacy and Safety of Luveltamab tazevibulin (STRO-002) in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (Included Fallopian Tube or Primary Peritoneal Cancers) expressing Folate Receptor alpha (FOLR1)
Phase 2
The objectives of this study are to evaluate the efficacy of luveltamab tazevibulin in subjects with relapsed platinum-resistant epithelial ovarian cancer expressing FOLR1. In addition to this main objective, the study will also assess the additional efficacy outcome measures, as well as the safety and tolerability of luveltamab tazevibulin in …
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib (UPROAR)
Phase 2
This study aims to learn more about the use of Mirvetuximab soravtansine and Olaparib as a maintenance therapy after completion of prior therapy for recurrent platinum sensitive ovarian, peritoneal and fallopian tube cancer. Mirvetuximab soravtansine is an effective antibody drug conjugate that targets folate receptor alpha. Olaparib is one of …
Phase I Clinical Trial of Adoptive Transfer of Autologous Folate Receptor alpha Redirected T Cells for Recurrent High Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer
Phase 1
This is a Phase I study evaluating the safety and feasibility of intraperitoneal administered lentiviral transduced MOv19-BBz CAR-T cells in 4 cohorts with or without cyclophosphamide + fludarabine in a 3+3 dose escalation design. Up to 18 evaluable subjects will be treated.
Zn-c3-005: A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer
Phase 2
A Phase 2 study to evaluate the clinical activity, safety, and potentially predictive biomarker profile of ZN-c3 in subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)
Phase 3
Purpose of the Study The purpose of this study is to find answers to the following research questions: · How effective is nemvaleukin alone and in combination with pembrolizumab in treating your epithelial ovarian, fallopian tube, or primary peritoneal cancer compared with chemotherapy? · What effect does nemvaleukin alone and …
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
Phase 1
NP-G2-044 Monotherapy Primary Objectives The primary objectives for patients receiving NP-G2-044 monotherapy are the following: 1) to identify the recommended Phase 2 dose (RP2D) of continuously dosed NP-G2-044 monotherapy (Mono-RP2D) and characterize its safety; and 2) to assess preliminary signals of NP-G2-044 anti-tumor efficacy when administered as continuously dosed monotherapy.
